 |
Drug Treatment Center Opens its Doors to Patients Seeking Alternative Addiction Treatment Methods
Traditional addiction treatment and drug rehabilitation programs have made strides in methodology for treating many types of addiction. Now Ambrosia, one of the freshest drug rehab facilities on the block, takes addiction treatment to a new level by incorporating chronic pain management to help those kick painkillers for good.
Drug Treatment Center Launches New Website: Brings Database of Drug Treatment Center Online
Ambrosia Treatment Center located in sunny North Palm Beach, Florida has brought online its extensive knowledge of drug rehabilitation and alcohol detox. Useful information about drug addiction, drug hazards and even a syndicated glossary of drug addiction terminology are all now available 24/7.
Free Medicine Foundation Helps Patients Taking Costly Cholesterol Drugs Receive Prescription Assistance
Free prescription drugs for people with high cholesterol and a history of heart problems are available to households with incomes as high as $80,000 through FreeMedicine.com. Most all brand-name prescription drugs are accessible through free or low-cost assistance programs.
Sober College Swings into Action with Trapeze Therapy Drug Treatment Program
Individuals entering the drug treatment program walk a high wire and attain other circus acrobatic skills, such as jumping on a large trampoline, learning to overcome fears and incorporate new life skills that will help them prepare to face uncomfortable situations in life. It is a drug rehab program designed to give them a sense of accomplishment, states Sober College Executive Director Loree Cohen.
Fighting Alcohol & Drug Addictions: 2 New Treatments for Eliminating Alcohol & Drug Addiction Forever
"I was lonely. I was just going to have one drink. I know that I can never just have one, and I didn't. I barely remember what happened. I'm lucky that I wasn't hurt too badly and that I didn't kill someone else. My new $35,000 Saab is gone and I had to spend the night in jail. I'm so ashamed. This is the last time. I?m done with drinking. You know the worst part? I want a drink right now! I wish I took your advice, and started the Prometa treatments."
Drugs.com, the Leading Online Clinical Drug Resource, Joins the Everyday Health Network: Everyday Health Network Traffic Surges Past 12 Million Uni
The Everyday Health Network (www.everydayhealth.com), published by Waterfront Media (www.waterfrontmedia.com), announced today that Drugs.com has joined the Network. Drugs.com, which attracts 3 million monthly unique visitors, is the leading source of clinical drug information online, providing advice on over 24,000 prescription drugs and over-the-counter medicines for consumers and professionals. As part of the multi-year partnership Waterfront Media will serve as Drug.com's official advertising representation.
|
 |
TrialStat, NewLab Clinical Research and BioTheraGene Form Newfoundland Labrador-Based Drug Discovery and Development Consortium
Consortium extends TrialStat's clinical data management (CDM) partner program.
Drug Treatment Center Launches New Website: Brings Database of Drug Treatment Center Online
Ambrosia Treatment Center located in sunny North Palm Beach, Florida has brought online its extensive knowledge of drug rehabilitation and alcohol detox. Useful information about drug addiction, drug hazards and even a syndicated glossary of drug addiction terminology are all now available 24/7.
Marillion Pharmaceuticals Initiates Clinical Development of Novel Anticancer Drug
Marillion Pharmaceuticals, Inc., a privately-held development-stage pharmaceutical company focused on novel therapeutics for the treatment of cancer, inflammatory and autoimmune diseases, announced today that its investigational new drug application (IND) has been cleared by the FDA. Marillion is now able to proceed with its planned Phase 1 human clinical trial for the company's lead product candidate, MN-201, an orally administered vitamin D5 analog for the treatment of cancer.
Lakeview Health Systems Drug Rehab Center, Specializing in Addiction Treatments Programs, Launches New Comprehensive Website
Lakeview Health Systems is a premier drug rehab center where recovery becomes a reality. Offering specialized addiction treatment programs and recovery plans including dual diagnosis, compassionate addiction treatment, and plans that are fully customizable to a patients needs, they are truly leading the way in addiction recovery. Their new drug treatment website fully showcases the state of the art drug rehab facility at Lakeview Health Systems and provides vital information regarding their specialty programs, admissions, travel arrangements, and treatment philosophy.
Professional Comparator Drug Sourcing and Procurement Services for Clinical Trials Growing in Popularity
Specialized clinical trial services have exploded in popularity in the past few years. One specialized service in particular has developed into a very important component of the clinical trial service industry. This service, comparator drug procurement, has become essential for clinical researchers.
Oncology CRO Publishes Free "Patient Safety in Oncology Clinical Trials" Abstract for Chief Medical Officers
Patient safety has always been the industry's focus during clinical trials. However, a recent spate of well-publicized patient safety issues has increased public scrutiny and the industry's desire to improve study quality, resulting in larger, longer, more expensive trials. In "Patient Safety in Oncology Clinical Trials," Dr. James Gourzis discusses patient safety as it pertains specifically to oncology clinical trials. The abstract is available for download on the Medelis Oncology CRO website.
Dynavax Receives Milestone from AstraZeneca : Novel Asthma/COPD Drug Candidate Nominated for Clinical Development
Dynavax Technologies, Inc. (NASDAQ:DVAX) today announced receipt of a $4.5 million milestone payment from its partner AstraZeneca AB for the nomination of candidate drug AZD1419 for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As part of this potential $136 million development and commercialization collaboration, AstraZeneca and Dynavax have initiated Investigational New Drug (IND) enabling studies with AZD1419 and plan to begin phase 1 clinical development in 2009.
|